This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Docetaxel

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Docetaxel is a taxoid which is indicated for the treatment of:

  • ovarian cancer resistant to platinum-based chemotherapy
  • prostate cancer - is recommended, within its licensed indications, as a treatment option for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more (1)
  • breast cancer resistant to first line treatment such as anthracyline
    • docetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer (2)

Reference:

  1. NICE (June 2006). Docetaxel for the treatment of hormone-refractory metastatic prostate cancer.
  2. NICE (September 2006). Docetaxel for the adjuvant treatment of early node-positive breast cancer

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.